UPM Institutional Repository

In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations


Citation

Lim, Cheng-Wei and Hamanaka, Gen and Liang, Anna C. and Chan, Su Jing and Ling, King-Hwa and Lo, Eng H. and Arai, Ken and Cheah, Pike See In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations. NeuroToxicology, 105. pp. 10-20. ISSN 0161-813X; eISSN: 1872-9711

Abstract

JAK-STAT signaling cascade has emerged as an ideal target for the treatment of myeloproliferative diseases, autoimmune diseases, and neurological disorders. Ruxolitinib (Rux), is an orally bioavailable, potent and selective Janus-associated kinase (JAK) inhibitor, proven to be effective to target activated JAK-STAT pathway in the diseases previously described. Unfortunately, limited studies have investigated the potential cytotoxic profile of Rux on other cell populations within the heterogenous CNS microenvironment. Two stem and progenitor cell populations, namely the oligodendrocyte precursor cells (OPCs) and neural stem/progenitor cells (NSPCs), are important for long-term maintenance and post-injury recovery response of the CNS. In light of the limited evidence, this study sought to investigate further the effect of Rux on proliferating and differentiating OPCs and NSPCs populations. In the present study, cultured rat OPCs and NSPCs were treated with various concentrations of Rux, ranging from 2 μM to 20 μM. The effect of Rux on proliferating OPCs (PDGF-R-α+) and proliferating NSPCs (nestin+) was assessed via a 3-day Rux treatment, whereas its effect on differentiating OPCs (MBP+/PDGFR- α+) and differentiating NSPCs (neurofilament+) was assessed after a 7-day treatment. Cytotoxicity of Rux was also assessed on OPC populations by examining its influence on cell death and DNA synthesis via YO-PRO-1/PI dual-staining and BrdU assay, respectively. The results suggest that Rux at a dosage above 10 μM reduces the number proliferating OPCs, likely via the induction of apoptosis. On the other hand, Rux treatment from 2.5 μM to 20 μM significantly reduces the number of differentiating OPCs by inducing necrosis. Meanwhile, Rux treatment has no observable untoward impact on NSPC cultures within the dosage range tested. Taken together, OPCs appears to be more vulnerable to the dosage effect of Rux, whereas NSPCs are not significantly impacted by Rux, suggesting a differential mechanism of actions of Rux on the cell types.


Download File

[img] Text
113251.pdf - Published Version
Restricted to Repository staff only

Download (11MB)

Additional Metadata

Item Type: Article
Divisions: Faculty of Medicine and Health Science
Malaysian Research Institute on Ageing
DOI Number: https://doi.org/10.1016/j.neuro.2024.08.004
Publisher: Elsevier
Keywords: Cytotoxicity; JAK inhibitor; Neural stem/progenitor cell; Oligodendrocyte precursor cell; Ruxolitinib
Depositing User: Scopus 2024
Date Deposited: 23 Oct 2024 06:19
Last Modified: 18 Nov 2024 04:37
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1016/j.neuro.2024.08.004
URI: http://psasir.upm.edu.my/id/eprint/113251
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item